Syncom Formulations Promoters File Annual SEBI SAST Shareholding Disclosure

Syncom Formulation (India) Ltd. ( (IN:SYNCOMF) ) has provided an announcement.

Syncom Formulations (India) Ltd. has reported that its promoters, Kedarmal Shankarlal Bankda and Vijay Shankarlal Bankda, along with persons acting in concert, have submitted their annual shareholding disclosure for the financial year ended 31 March 2026 to the company’s audit committee in compliance with Regulation 31(4) of SEBI’s SAST Regulations, 2011. The company has also informed both BSE and NSE of these submissions and requested that the disclosures be hosted on the exchanges’ websites, underscoring ongoing regulatory compliance and transparency regarding promoter holdings for investors and other stakeholders.

More about Syncom Formulation (India) Ltd.

Syncom Formulations (India) Ltd. operates in the pharmaceuticals and formulations sector, focusing on manufacturing and marketing medicinal products for the domestic and potentially export markets. The company is listed on both BSE and the National Stock Exchange of India, reflecting its access to public capital markets and regulatory oversight under Indian securities laws.

Average Trading Volume: 223,097

Technical Sentiment Signal: Hold

Current Market Cap: 10.62B INR

See more insights into SYNCOMF stock on TipRanks’ Stock Analysis page.